Ombitasvir, Paritaprevir, and Ritonavir and Zolpidem Oral, Oromucosal
Determining the interaction of Ombitasvir, Paritaprevir, and Ritonavir and Zolpidem Oral, Oromucosal and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.
Professional:Use of drugs that inhibit the isoenzyme CYP450 3A4 may decrease the metabolism and increase the plasma levels of zolpidem. This can result in increased clinical effectiveness and risk of toxicity associated with zolpidem. Monitoring for signs and symptoms of altered zolpidem effect is recommended. Patients should be advised to notify their doctor if they experience nausea, vomiting, diarrhea, confusion, daytime sedation, dizziness, or unconsciousness. A reduction in zolpidem dosage may be necessary.
- "Multum Information Services, Inc. Expert Review Panel"
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Agencia EspaƱola de Medicamentos y Productos Sanitarios Healthcare "Centro de informaciĆ³n online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):
- Cerner Multum, Inc. "Australian Product Information." O 0
Generic Name: ombitasvir / paritaprevir / ritonavir
Brand name: Technivie
Synonyms: n.a.
Generic Name: zolpidem
Brand name: Ambien, Ambien CR, Edluar, Intermezzo, ZolpiMist
Synonyms: Zolpidem
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Ombitasvir, Paritaprevir, and Ritonavir-Zolpidem Sublingual
- Ombitasvir, Paritaprevir, and Ritonavir-Zolpidem Sublingual Tablets (Edluar)
- Ombitasvir, Paritaprevir, and Ritonavir-Zolpidem Sublingual Tablets (Intermezzo)
- Ombitasvir, Paritaprevir, and Ritonavir-Zolpidem Tablets
- Ombitasvir, Paritaprevir, and Ritonavir-Zolpidem Tartrate
- Ombitasvir, Paritaprevir, and Ritonavir-ZolpiMist
- Zolpidem Oral, Oromucosal-Ombitasvir, paritaprevir, ritonavir and dasabuvir
- Zolpidem Oral, Oromucosal-Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets
- Zolpidem Oral, Oromucosal-Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Tablets
- Zolpidem Oral, Oromucosal-Omeclamox-Pak
- Zolpidem Oral, Oromucosal-Omega-3 Fatty Acid Capsules
- Zolpidem Oral, Oromucosal-Omega-3 Fatty Acids